Open AccessHematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car
Author(s) -
Michael Scordo,
Richard J. Lin,
Craig S. Sauter
Publication year - 2019
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000515
Subject(s) - medicine , salvage therapy , oncology , transplantation , plerixafor , context (archaeology) , lymphoma , hematopoietic cell , chimeric antigen receptor , chemotherapy , cancer , stem cell , immunotherapy , haematopoiesis , cxcr4 , biology , paleontology , genetics , chemokine , receptor
Second-line platinum-based salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic-cell transplantation (AHCT) has remained the standard of care (SOC) for relapsed and primary refractory (r/r) diffuse large B-cell lymphoma (DLBCL) for greater than 2 decades. In the postrituximab era, this strategy has yielded disappointing outcomes for r/r patients with curability in less one-quarter of the patients by intention-to-treat.